Temozolomide in Treating Patients With Metastatic Germ Cell Tumors That Have Not Responded to Cisplatin
|ClinicalTrials.gov Identifier: NCT00006043|
Recruitment Status : Completed
First Posted : April 2, 2004
Last Update Posted : June 5, 2013
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of temozolomide in treating patients who have metastatic germ cell tumors that have not responded to cisplatin.
|Condition or disease||Intervention/treatment||Phase|
|Ovarian Cancer Testicular Germ Cell Tumor||Drug: temozolomide||Phase 2|
OBJECTIVES: I. Determine the efficacy of temozolomide in patients with cisplatin refractory metastatic germ cell tumors. II. Determine the safety of this treatment in these patients.
OUTLINE: Patients receive oral temozolomide on days 1-5. Treatment repeats every 28 days for a maximum of 6 courses in the absence of disease progression or unacceptable toxicity.
PROJECTED ACCRUAL: A total of 14-25 patients will be accrued for this study over 25 months.
|Study Type :||Interventional (Clinical Trial)|
|Official Title:||Phase II Trial of Temozolomide in Patients With Cisplatin-Refractory Germ Cell Tumors|
|Study Start Date :||February 2000|
|Primary Completion Date :||November 2001|
|Study Completion Date :||November 2001|
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00006043
|United States, New York|
|Memorial Sloan-Kettering Cancer Center|
|New York, New York, United States, 10021|
|Study Chair:||Robert J. Motzer, MD||Memorial Sloan Kettering Cancer Center|